A 52-year-old man with a 10-year history of hypertension and type 2 diabetes mellitus presents to the cardiology clinic for evaluation of chest discomfort on exertion. His blood pressure is 148/92 mmHg and heart rate is 88 bpm. ECG shows evidence of old inferior wall myocardial infarction. His current medications include metformin and amlodipine. The cardiologist decides to initiate beta-blocker therapy. Which of the following beta-blockers would be the MOST appropriate choice for this patient, and why?

Explanation

## Clinical Context This patient has multiple indications for beta-blocker therapy: post-myocardial infarction, hypertension, and angina. The presence of diabetes mellitus is a critical consideration when selecting a specific beta-blocker. ## Why Carvedilol Is Optimal **Key Point:** Carvedilol is a non-selective beta-blocker with combined α₁-adrenergic blocking and antioxidant properties. It is the preferred agent in post-MI patients with diabetes because it: 1. **Reduces mortality post-MI** — demonstrated in COPERNICUS and CAPRICORN trials 2. **Preserves insulin sensitivity** — unlike atenolol and metoprolol, which can worsen glucose control 3. **Provides vasodilation** — via α₁-blockade, reducing afterload and improving hemodynamics 4. **Has antioxidant effects** — protective in diabetic patients prone to oxidative stress **High-Yield:** Carvedilol and nebivolol are the only beta-blockers that do NOT adversely affect glucose metabolism and may even improve insulin sensitivity. This makes them ideal in diabetic patients. **Clinical Pearl:** Post-MI patients benefit from beta-blockers that reduce mortality (carvedilol, metoprolol succinate, bisoprolol). Atenolol, despite being cardioselective, has NOT shown mortality benefit in post-MI trials and worsens glucose control. ## Comparison Table | Property | Carvedilol | Atenolol | Labetalol | Propranolol | | --- | --- | --- | --- | --- | | Selectivity | Non-selective | β₁-selective | Non-selective | Non-selective | | α-Blockade | Yes | No | Yes | No | | Post-MI mortality benefit | Yes | No | No | No | | Effect on glucose | Neutral/↑ sensitivity | ↓ Sensitivity | Neutral | ↓ Sensitivity | | Antioxidant | Yes | No | No | No | | Intrinsic sympathomimetic activity | No | No | No | No | **Mnemonic:** **CABIN** — Carvedilol, Bisoprolol (and Nebivolol) are the only beta-blockers safe in diabetes. ## Why Other Options Are Suboptimal - **Atenolol:** Cardioselective but worsens glucose control and lacks post-MI mortality benefit - **Labetalol:** Good for hypertension but not first-line post-MI; less evidence for mortality reduction - **Propranolol:** Non-selective, worsens glucose control, and is not preferred in post-MI settings [cite:KD Tripathi 8e Ch 12]